目的:探讨MARCH2和CFTR在结直肠癌中的蛋白表达及与临床病理参数的相关性。方法:采用免疫组织化学SP法检测125例结直肠癌和30例正常结直肠黏膜组织中MARCH2和CFTR的表达,并复习相关文献。结果:在125例结直肠癌组织中,MARCH2和CFTR的阳...目的:探讨MARCH2和CFTR在结直肠癌中的蛋白表达及与临床病理参数的相关性。方法:采用免疫组织化学SP法检测125例结直肠癌和30例正常结直肠黏膜组织中MARCH2和CFTR的表达,并复习相关文献。结果:在125例结直肠癌组织中,MARCH2和CFTR的阳性表达率分别为84.8%和8.8%,而在非肿瘤性肠组织中,这两种表达率的阳性率分别为6.7%和90.0%。MARCH2的阳性表达与肿瘤大小、深部浸润、淋巴结转移和TNM分期密切相关。此外,CFTR表达的缺失与分化不良、淋巴结转移和TNM分期显著相关。此外,MARCH2和CFTR表达之间存在显著负相关。结论:MARCH2在结直肠癌中高度表达,与肿瘤大小、深部浸润、淋巴结转移和TNM分期等预后不良参数有关。相比之下,CFTR在结直肠癌中几乎不表达,CFTR表达缺失与分化不良、淋巴结转移和TNM分期显著相关。MARCH2可能通过与CFTR的相互作用在结直肠癌的发展中发挥重要作用。它们可能成为结直肠癌诊断、治疗和预后评估的分子标志物。Aims: This study aimed to investigate whether the expressions of MARCH2 and CFTR in colorectal carcinomas were associated with clinicopathological parameters. Methods: The expressions of MARCH2 and CFTR were examined in 125 cases of colorectal carcinomas and 30 normal colorectal tissues using immunohistochemical staining. Results: The positive rates of MARCH2 and CFTR expressions in 125 cases of colorectal carcinoma were 84.8% and 8.8% respectively, whereas the positive expression rates of MARCH2 and CFTR in non-tumor colorectal tissues were 6.7% and 90.0% respectively. The positive expressions of MARCH2 were closely related to tumor size, deep invasion, lymph node metastasis and advanced TNM stage. In addition, loss of expression of CFTR was significantly associated with poor differentiation, lymph node metastasis and advanced TNM stage. Furthermore, there were significant negative correlations between MARCH2 and CFTR expression. Conclusions: MARCH2 is highly expressed in colorectal carcinomas, and is associated with poor prognostic parameters such as tumor size, deep invasion, lymph node metastasis and advanced TNM stage. In contrast, CFTR barely expressed in colorectal carcinomas, and loss of expression of CFTR was significantly associated with poor differentiation, lymph node metastasis and advanced TNM stage. MARCH2 may play an important role in the development of colorectal carcinoma through interaction with CFTR. They may become molecular markers for diagnosis, treatment and prognostic evaluation of colorectal carcinomas.展开更多
文摘目的:探讨MARCH2和CFTR在结直肠癌中的蛋白表达及与临床病理参数的相关性。方法:采用免疫组织化学SP法检测125例结直肠癌和30例正常结直肠黏膜组织中MARCH2和CFTR的表达,并复习相关文献。结果:在125例结直肠癌组织中,MARCH2和CFTR的阳性表达率分别为84.8%和8.8%,而在非肿瘤性肠组织中,这两种表达率的阳性率分别为6.7%和90.0%。MARCH2的阳性表达与肿瘤大小、深部浸润、淋巴结转移和TNM分期密切相关。此外,CFTR表达的缺失与分化不良、淋巴结转移和TNM分期显著相关。此外,MARCH2和CFTR表达之间存在显著负相关。结论:MARCH2在结直肠癌中高度表达,与肿瘤大小、深部浸润、淋巴结转移和TNM分期等预后不良参数有关。相比之下,CFTR在结直肠癌中几乎不表达,CFTR表达缺失与分化不良、淋巴结转移和TNM分期显著相关。MARCH2可能通过与CFTR的相互作用在结直肠癌的发展中发挥重要作用。它们可能成为结直肠癌诊断、治疗和预后评估的分子标志物。Aims: This study aimed to investigate whether the expressions of MARCH2 and CFTR in colorectal carcinomas were associated with clinicopathological parameters. Methods: The expressions of MARCH2 and CFTR were examined in 125 cases of colorectal carcinomas and 30 normal colorectal tissues using immunohistochemical staining. Results: The positive rates of MARCH2 and CFTR expressions in 125 cases of colorectal carcinoma were 84.8% and 8.8% respectively, whereas the positive expression rates of MARCH2 and CFTR in non-tumor colorectal tissues were 6.7% and 90.0% respectively. The positive expressions of MARCH2 were closely related to tumor size, deep invasion, lymph node metastasis and advanced TNM stage. In addition, loss of expression of CFTR was significantly associated with poor differentiation, lymph node metastasis and advanced TNM stage. Furthermore, there were significant negative correlations between MARCH2 and CFTR expression. Conclusions: MARCH2 is highly expressed in colorectal carcinomas, and is associated with poor prognostic parameters such as tumor size, deep invasion, lymph node metastasis and advanced TNM stage. In contrast, CFTR barely expressed in colorectal carcinomas, and loss of expression of CFTR was significantly associated with poor differentiation, lymph node metastasis and advanced TNM stage. MARCH2 may play an important role in the development of colorectal carcinoma through interaction with CFTR. They may become molecular markers for diagnosis, treatment and prognostic evaluation of colorectal carcinomas.
